The Celiac Disease Center at Columbia University, the premier center for celiac disease research and treatment, unveiled the I Didn’t Know video campaign, offering an inside look at the serious impact of celiac disease on patients at the 13th Anniversary gala on November 13th in New York City. The series chronicles the lives of several patients experiencing a wide range of debilitating symptoms associated with undiagnosed celiac disease, including an inability to walk, developmental delays, multiple miscarriages and infertility.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7322351-celiac-disease-center-at-columbia-university-public-service-announcements-and-gala/
Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world’s smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children’s hearts. This dime-sized new valve is the first and only pediatric mechanical heart valve developed for newborns and infants, and offers hope for pediatric patients in urgent need of treatment who have no other approved options.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280551-abbott-pediatric-heart-valve-fda-approval/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Many people equate a conversation about hospice as being told they must give up. However, more than 1 million people across the nation have learned just the opposite. They’ve been touched by the National Hospice and Palliative Care Organization’s “Moments of Life: Made Possible by Hospice” campaign since its launch on May 15, 2014. The campaign’s intent is to debunk this myth, and show that hospice focuses on compassionate, person-centered care, which enables special moments and memories at the end of life for patients and loved ones.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7154752-national-hospice-and-palliative-care-organization-nhpco-moments-of-life-psa/
Dr. Maurice Rawlings, MD, a heart surgeon, has written a number of books on the near-death experience and clearly shows from his own practice and the experiences of his patients, that not everyone goes to the light when they die, where there is total love. He has written of many patients being resuscitated on the operating table and speaking about being in hell, where there was a real devil and demons, and where the inhabitants were tormented with fire. Dr. Rawlings writes that these people are a lot more reluctant to talk about it than those who went to the good place. DivineRevelations.info
The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
The Heart Rhythm Society (HRS), through its efforts during Atrial Fibrillation Awareness Month in September and throughout the year, is working to raise awareness of the increased prevalence of the disease and the associated risk of stroke in patients living with atrial fibrillation (AFib). Today, HRS releases a new public service announcement (PSA) as part of its ongoing work to educate Americans about AFib, the most common heart arrhythmia, and how it increases one’s risk of stroke fivefold. The PSA can be viewed by clicking here.
AFib affects more than three million Americans and it is estimated that 12 to 16 million Americans will have AFib by 2050. AFib occurs when the upper chambers of the heart (the atria) fibrillate, or “quiver,” which causes a rapid, irregular heart rhythm. The normal heart rate for an adult is between 60 and 100 beats every minute. When the heart is experiencing AFib, the atria can beat over 300 times every minute.
To view the multimedia release go to:
http://www.multivu.com/players/English/7312151-heart-rhythm-society-afib-stroke-psa/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
